|
1
|
Haddad RI and Shin DM: Recent advances in
head and neck cancer. N Engl J Med. 359:1143–1154. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen YJ, Chang JT, Liao CT, Wang HM, Yen
TC, Chiu CC, Lu YC, Li HF and Cheng AJ: Head and neck cancer in the
betel quid chewing area: Recent advances in molecular
carcinogenesis. Cancer Sci. 99:1507–1514. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gibson MK and Forastiere AA: Reassessment
of the role of induction chemotherapy for head and neck cancer.
Lancet Oncol. 7:565–574. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang Z, Filho MS and Nör JE: The biology
of head and neck cancer stem cells. Oral Oncol. 48:1–9. 2012.
View Article : Google Scholar :
|
|
5
|
Rosen JM and Jordan CT: The increasing
complexity of the cancer stem cell paradigm. Science.
324:1670–1673. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lo WL, Yu CC, Chiou GY, Chen YW, Huang PI,
Chien CS, Tseng LM, Chu PY, Lu KH, Chang KW, et al: MicroRNA-200c
attenuates tumour growth and metastasis of presumptive head and
neck squamous cell carcinoma stem cells. J Pathol. 223:482–495.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen C, Zimmermann M, Tinhofer I, Kaufmann
AM and Albers AE: Epithelial-to-mesenchymal transition and cancer
stem(-like) cells in head and neck squamous cell carcinoma. Cancer
Lett. 338:47–56. 2013. View Article : Google Scholar
|
|
8
|
Major AG, Pitty LP and Farah CS: Cancer
stem cell markers in head and neck squamous cell carcinoma. Stem
Cells Int. 2013:3194892013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Raimondi C, Gianni W, Cortesi E and
Gazzaniga P: Cancer stem cells and epithelial-mesenchymal
transition: Revisiting minimal residual disease. Curr Cancer Drug
Targets. 10:496–508. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Polyak K and Weinberg RA: Transitions
between epithelial and mesenchymal states: Acquisition of malignant
and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell
Biol. 7:131–142. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Song LB, Li J, Liao WT, Feng Y, Yu CP, Hu
LJ, Kong QL, Xu LH, Zhang X, Liu WL, et al: The polycomb group
protein Bmi-1 represses the tumor suppressor PTEN and induces
epithelial-mesenchymal transition in human nasopharyngeal
epithelial cells. J Clin Invest. 119:3626–3636. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang MH, Hsu DS, Wang HW, Wang HJ, Lan HY,
Yang WH, Huang CH, Kao SY, Tzeng CH, Tai SK, et al: Bmi1 is
essential in Twist1-induced epithelial-mesenchymal transition. Nat
Cell Biol. 12:982–992. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gil J, Bernard D and Peters G: Role of
polycomb group proteins in stem cell self-renewal and cancer. DNA
Cell Biol. 24:117–125. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pasini D, Bracken AP and Helin K: Polycomb
group proteins in cell cycle progression and cancer. Cell Cycle.
3:396–400. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Crea F, Duhagon Serrat MA, Hurt EM, Thomas
SB, Danesi R and Farrar WL: BMI1 silencing enhances docetaxel
activity and impairs antioxidant response in prostate cancer. Int J
Cancer. 128:1946–1954. 2011. View Article : Google Scholar
|
|
18
|
Guo BH, Feng Y, Zhang R, Xu LH, Li MZ,
Kung HF, Song LB and Zeng MS: Bmi-1 promotes invasion and
metastasis, and its elevated expression is correlated with an
advanced stage of breast cancer. Mol Cancer. 10:102011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang E, Bhattacharyya S, Szabolcs A,
Rodriguez-Aguayo C, Jennings NB, Lopez-Berestein G, Mukherjee P,
Sood AK and Bhattacharya R: Enhancing chemotherapy response with
Bmi-1 silencing in ovarian cancer. PLoS One. 6:e179182011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tong YQ, Liu B, Zheng HY, He YJ, Gu J, Li
F and Li Y: BMI-1 autoantibody as a new potential biomarker for
cervical carcinoma. PLoS One. 6:e278042011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim JH, Yoon SY, Kim CN, Joo JH, Moon SK,
Choe IS, Choe YK and Kim JW: The Bmi-1 oncoprotein is overexpressed
in human colorectal cancer and correlates with the reduced
p16INK4a/p14ARF proteins. Cancer Lett. 203:217–224. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vonlanthen S, Heighway J, Altermatt HJ,
Gugger M, Kappeler A, Borner MM, van Lohuizen M and Betticher DC:
The bmi-1 oncoprotein is differentially expressed in non-small cell
lung cancer and correlates with INK4A-ARF locus expression. Br J
Cancer. 84:1372–1376. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
He XT, Cao XF, Ji L, Zhu B, Lv J, Wang DD,
Lu PH and Cui HG: Association between Bmi1 and clinicopathological
status of esophageal squamous cell carcinoma. World J
Gastroenterol. 15:2389–2394. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu JH, Song LB, Zhang X, Guo BH, Feng Y,
Li XX, Liao WT, Zeng MS and Huang KH: Bmi-1 expression predicts
prognosis for patients with gastric carcinoma. J Surg Oncol.
97:267–272. 2008. View Article : Google Scholar
|
|
25
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Soini Y, Tuhkanen H, Sironen R, Virtanen
I, Kataja V, Auvinen P, Mannermaa A and Kosma VM: Transcription
factors zeb1, twist and snai1 in breast carcinoma. BMC Cancer.
11:732011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gemmill RM, Roche J, Potiron VA, Nasarre
P, Mitas M, Coldren CD, Helfrich BA, Garrett-Mayer E, Bunn PA and
Drabkin HA: ZEB1-responsive genes in non-small cell lung cancer.
Cancer Lett. 300:66–78. 2011. View Article : Google Scholar
|
|
28
|
Zhang GJ, Zhou T, Tian HP, Liu ZL and Xia
SS: High expression of ZEB1 correlates with liver metastasis and
poor prognosis in colorectal cancer. Oncol Lett. 5:564–568.
2013.PubMed/NCBI
|
|
29
|
Yokobori T, Suzuki S, Tanaka N, Inose T,
Sohda M, Sano A, Sakai M, Nakajima M, Miyazaki T, Kato H, et al:
MiR-150 is associated with poor prognosis in esophageal squamous
cell carcinoma via targeting the EMT inducer ZEB1. Cancer Sci.
104:48–54. 2013. View Article : Google Scholar
|
|
30
|
Gheldof A, Hulpiau P, van Roy F, De Craene
B and Berx G: Evolutionary functional analysis and molecular
regulation of the ZEB transcription factors. Cell Mol Life Sci.
69:2527–2541. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nakamura E, Kozaki K, Tsuda H, Suzuki E,
Pimkhaokham A, Yamamoto G, Irie T, Tachikawa T, Amagasa T, Inazawa
J, et al: Frequent silencing of a putative tumor suppressor gene
melatonin receptor 1 A (MTNR1A) in oral squamous-cell carcinoma.
Cancer Sci. 99:1390–1400. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Remmele W and Stegner HE: Recommendation
for uniform definition of an immunoreactive score (IRS) for
immunohisto-chemical estrogen receptor detection (ER-ICA) in breast
cancer tissue. Pathologe. 8:138–140. 1987.In German. PubMed/NCBI
|
|
33
|
Nieto MA: The ins and outs of the
epithelial to mesenchymal transition in health and disease. Annu
Rev Cell Dev Biol. 27:347–376. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kang MK, Kim RH, Kim SJ, Yip FK, Shin KH,
Dimri GP, Christensen R, Han T and Park NH: Elevated Bmi-1
expression is associated with dysplastic cell transformation during
oral carcinogenesis and is required for cancer cell replication and
survival. Br J Cancer. 96:126–133. 2007. View Article : Google Scholar
|
|
35
|
Häyry V, Mäkinen LK, Atula T, Sariola H,
Mäkitie A, Leivo I, Keski-Säntti H, Lundin J, Haglund C and
Hagström J: Bmi-1 expression predicts prognosis in squamous cell
carcinoma of the tongue. Br J Cancer. 102:892–897. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Balasubramanian S, Lee K, Adhikary G,
Gopalakrishnan R, Rorke EA and Eckert RL: The Bmi-1 polycomb group
gene in skin cancer: Regulation of function by
(-)-epigallocatechin-3-gallate. Nutr Rev. 66(Suppl 1): S65–S68.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Siddique HR and Saleem M: Role of BMI1, a
stem cell factor, in cancer recurrence and chemoresistance:
Preclinical and clinical evidences. Stem Cells. 30:372–378. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen ML, Liang LS and Wang XK: miR-200c
inhibits invasion and migration in human colon cancer cells
SW480/620 by targeting ZEB1. Clin Exp Metastasis. 29:457–469. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chu PY, Hu FW, Yu CC, Tsai LL, Yu CH, Wu
BC, Chen YW, Huang PI and Lo WL: Epithelial-mesenchymal transition
transcription factor ZEB1/ZEB2 co-expression predicts poor
prognosis and maintains tumor-initiating properties in head and
neck cancer. Oral Oncol. 49:34–41. 2013. View Article : Google Scholar
|
